In Brief: First Response, DXM bills, J&J OTCs, Nu Skin record
This article was originally published in The Tan Sheet
Executive Summary
First Response Gold makes earliest detection claim; Virginia passes DXM age restriction; J&J “confident in communicating” on OTCs; Nu Skin reports record quarter, year; and more In Brief.
You may also be interested in...
FSA/HSA Coverage Tops CHPA 2014 Legislative Goals
The Consumer Healthcare Products Association’s No. 1 legislative priority in 2014 is restoring OTC coverage by flexible spending and health savings accounts, followed by a “close No. 2” goal of establishing an age requirement to buy DXM products. Other goals include protecting access to PSE products and blocking take-back programs.
J&J Will Boost OTC Marketing Once Reliable Production Returns
Johnson & Johnson CEO Alex Gorsky says he expects 75% of OTC products previously recalled to be back on the market in 2013, and the firm will begin prioritizing marketing efforts once a consistent supply of products is restored. The McNeil Fort Washington facility will remain offline another year.
DXM legislation
The "Dextromethorphan Distribution Act of 2006" (H.R. 5280) now has 13 cosponsors and has been referred to the House Committee on Energy & Commerce, the Consumer Healthcare Products Association states July 26. The bill would allow FDA to limit the distribution of the bulk ingredient to only those people or entities that are registered with the agency and would make it more difficult for teens to abuse the drug. Stephen Pasierb of the Partnership for a Drug-Free America spoke about CHPA's efforts to curb abuse of OTCs during a July 26 hearing held by the House Government Reform Subcommittee on Criminal Justice, Drug Policy & Human Resources. CHPA and the Partnership launched a public service campaign in May to inform consumers about the dangers of abusing DXM and other Rx and OTC drugs (1"The Tan Sheet" May 22, 2006, p. 4)...